

**Kyowa Hakko Kirin Co., Ltd.****Appendix to the Fiscal 2011 Consolidated Financial Statements**

(January 1, 2011 - December 31, 2011)

<b>Index</b>	<b>Page</b>
I. Consolidated Financial Results	
1. Income	1
2. Results by segment	1
3. Non-operating income/expenses	2
4. Extraordinary income/loss	2
5. R&D expenses	3
6. Capital expenditure	3
7. Depreciation expenses	3
8. Employee numbers	3
9. Exchange rates	3
II. Consolidated Subsidiaries and Affiliates	4
III. Non-Consolidated Net Sales by Division	5
1. Kyowa Hakko Kirin	5
2. ProStrakan	6
3. Kyowa Hakko Bio	6
4. Kyowa Hakko Chemical	6
R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the fiscal year ending December 31, 2011. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

## I. Consolidated Financial Results

### 1. Trends in income

Millions of yen, rounded down

	FY 2010 results		FY 2011 results					FY 2012 forecasts	
	January 1 to June 30	January 1 to December 31 (A)	January 1 to June 30	January 1 to December 31 (forecast as at 7/20)	January 1 to December 31 (B)	Change		January 1 to June 30	January 1 to December 31
						Amount (B-A)	%		
<b>Net sales</b>	203,466	413,738	186,367	342,000	343,722	(70,016)	83%	163,000	326,000
<b>Gross Profit</b>	92,763	190,979	100,234	--	197,555	6,576	103%	--	--
Selling, general and administrative expenses	71,071	145,568	70,297	--	150,940	5,371	104%	--	--
<b>Operating income (prior to amortization of goodwill)</b>	26,344	54,713	34,576	52,767	55,881	1,167	102%	27,127	57,255
<b>Operating income</b>	21,692	45,410	29,936	43,500	46,614	1,204	103%	22,500	48,000
Other income	3,120	5,201	1,316	--	2,233	(2,967)		--	--
Other expenses	2,478	4,111	1,040	--	2,093	(2,017)		--	--
<b>Ordinary income</b>	22,334	46,500	30,212	44,500	46,754	254	101%	19,500	42,500
Extraordinary income	1,082	2,822	8,421	--	7,332	4,510		--	--
Extraordinary expenses	5,775	7,023	5,363	--	7,903	880		--	--
<b>Net income before income taxes</b>	17,641	42,299	33,270	46,500	46,183	3,884	109%	19,500	41,000
Corporate, local and enterprise taxes	7,718	20,040	15,507	--	20,489	448		--	--
Income from minority interests	21	61	44	--	86	25		--	--
<b>Net income</b>	9,901	22,197	17,718	25,500	25,608	3,411	115%	8,500	20,000
<b>Comprehensive income</b>	--	16,419	--	--	18,693	2,273	114%	--	--
EPS before goodwill amortization (¥/share)	25.55	55.29	39.24	61.02	61.50	6.21	111%	23.88	53.28

Notes : 1. Figures before goodwill amortization represent amounts prior to subtraction of the goodwill amortization\* which occurred as a result of the reverse acquisition (exchange of Kirin Pharma Co. stock) implemented in April 2008.

\* Goodwill amortization resulting from the acquisition of all outstanding shares of ProStrakan Group plc is not included in these adjusted figures.

2. On April 21, 2011, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan Group plc and as a result ProStrakan Group, and its ten subsidiaries were newly included in the scope of consolidation. In terms of accounting treatment, June 30, 2011 will be considered as the date that the acquisition was completed and therefore results from ProStrakan have not been included in the consolidated financial results for the first half of the current fiscal year. Financial results from ProStrakan as of July have been included in the financial results.

### 2. Trends in results by segment

#### (1) Results by operating segment

Millions of yen, rounded down

	FY 2010 results		FY 2011 results					FY 2012 forecasts	
	January 1 to June 30	January 1 to December 31 (A)	January 1 to June 30	January 1 to December 31 (forecast as at 7/20)	January 1 to December 31 (B)	Change		January 1 to June 30	January 1 to December 31
						Amount (B-A)	%		
<b>Net sales</b>	203,466	413,738	186,367	342,000	343,722	(70,016)	83%	163,000	326,000
Pharmaceuticals	103,475	210,362	112,534	225,000	229,339	18,977	109%	120,000	242,000
Bio-Chemicals	44,186	84,236	40,360	80,000	77,563	(6,673)	92%	40,000	78,000
Chemicals	61,289	130,018	33,550	33,550	33,550	(96,468)	--	--	--
Other	5,082	10,499	5,306	11,000	10,659	160	102%	5,000	10,000
Total	214,034	435,116	191,752	349,550	351,113	(84,003)	81%	165,000	330,000
Eliminations	(10,567)	(21,377)	(5,384)	(7,550)	(7,390)	13,987	35%	(2,000)	(4,000)
<b>Operating income</b>	21,692	45,410	29,936	43,500	46,614	1,204	103%	22,500	48,000
<i>*Before goodwill amortization</i>	26,344	54,713	34,576	52,767	55,881	1,167	102%	27,127	57,255
Pharmaceuticals	17,993	35,857	25,145	37,500	41,314	5,457	115%	21,500	45,700
Bio-Chemicals	22,307	44,485	29,459	46,129	49,942	5,457	112%	25,814	54,329
Chemicals	1,853	3,275	2,519	3,500	2,896	(379)	88%	800	2,000
Other	2,166	3,901	2,832	4,126	3,521	(379)	90%	1,113	2,626
Chemicals	1,589	5,678	2,135	2,135	2,135	(3,543)	--	--	--
Other	1,614	5,728	2,147	2,147	2,147	(3,580)	(-)	(-)	(-)
Other	150	363	148	365	360	(2)	99%	200	300
Total	21,587	45,175	29,948	43,500	46,706	1,531	103%	22,500	48,000
Eliminations	26,239	54,478	34,588	52,767	55,973	1,494	103%	27,127	57,255
Eliminations	105	235	(12)	--	(92)	(327)	--	--	--

Notes: 1. Figures representing amounts before goodwill amortization have been italicized.

2. As of the period under review, Kyowa Hakko Kirin has adopted "Accounting Standards Related to the Disclosure of Segment Information". Since the segment classification methods used to classify business by segment are the same as those used previously, we are able to make comparisons with the previous year.

3. The Chemicals Business was discontinued at the end of the first quarter following the transfer of all shares of Kyowa Hakko Chemical on March 31, 2011. As a result, income from Chemicals was consolidated on the Statements of Income only until March 31, 2011.

## (2) Regional sales

Millions of yen, rounded down

	FY 2010 results				FY 2011 results			
	January 1 to June 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales
<b>Japan sales</b>	161,229	79.2%	328,596	79.4%	148,987	79.9%	272,568	79.3%
<b>Overseas sales</b>	42,236	20.8%	85,141	20.6%	37,379	20.1%	71,154	20.7%
America	12,977	6.4%	23,467	5.7%	10,456	5.6%	20,071	5.8%
Europe	10,779	5.3%	21,477	5.2%	10,919	5.9%	25,169	7.3%
Asia	18,114	8.9%	39,689	9.6%	15,772	8.5%	25,426	7.4%
Other regions	364	0.2%	507	0.1%	231	0.1%	486	0.1%
<b>Total consolidated net sales</b>	<b>203,466</b>	<b>100.0%</b>	<b>413,738</b>	<b>100.0%</b>	<b>186,367</b>	<b>100.0%</b>	<b>343,722</b>	<b>100.0%</b>

\* Sales classified by region or country based on location of customer.

## 3. Trends in non-operating income/expenses

Millions of yen, rounded down

	FY 2010 results		FY 2011 results	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
<b>Non-operating income</b>	3,120	5,201	1,316	2,233
Interest income	221	362	193	497
Dividends income	485	844	303	536
Foreign exchange gains	--	--	112	--
Gain on revaluation of derivatives	685	414	--	--
Income from investment in equity method	626	1,074	141	199
Other	1,102	2,505	565	1,000
<b>Non-operating expenses</b>	2,478	4,111	1,040	2,093
Interest expenses	122	199	77	135
Foreign exchange loss	1,143	1,280	--	154
Loss on revaluation of derivatives	--	--	32	142
Loss on disposal of non-current assets	608	1,493	313	670
Other	604	1,138	617	990

## 4. Trends in extraordinary income / loss

Millions of yen, rounded down

	FY 2010 results		FY 2011 results	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
<b>Extraordinary income</b>	1,082	2,822	8,421	7,332
Gain on sales of affiliates' stocks	--	--	8,320	7,217
Reversal of allowance for doubtful accounts	107	139	100	115
Gain on sale of investment securities	120	1,828	--	--
Gain on negative goodwill	854	854	--	--
<b>Extraordinary loss</b>	5,775	7,023	5,363	7,903
Loss on valuation of investment securities	2,588	1,473	3,043	2,374
Advisory fee	--	--	1,030	1,098
Impairment loss	--	1,374	200	769
Loss from sale of investment securities	--	101	--	692
Loss on disaster	--	--	302	650
Loss from sale of fixed assets	189	189	--	635
Non-recurring depreciation on non-current assets	1,225	1,225	--	477
Loss on adjustment for changes of accounting standard for asset retirement	--	--	447	447
Loss on business liquidation	--	--	--	419
Loss on liquidation of affiliates	--	--	209	209
Provision for point card certificates for prior periods	--	--	128	128
Loss on revision of retirement benefit plan	1,771	1,771	--	--
Provision for environmental measures	--	887	--	--

## 5. Trends in R&D Expenses

Billions of yen, rounded down

	FY 2010 results		FY 2011 results		FY 2012 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
<b>R&amp;D expenses (Consolidated)</b>	21.4	44.2	22.2	47.9	23.9	46.1
R&D to net sales ratio	10.5%	10.7%	11.9%	14.0%	14.7%	14.2%
Pharmaceuticals (R&D to net sales ratio)	19.3 18.7%	40.0 19.0%	20.4 18.2%	44.5 19.4%	22.3 18.6%	42.9 17.7%
Bio-Chemicals	1.5	3.2	1.5	3.2	1.5	3.1
Chemicals	0.4	1.0	0.2	0.2	--	--
Other	--	--	--	--	--	--

## 6. Trends in Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2010 results		FY 2011 results		FY 2012 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
<b>Capital expenditure (Consolidated)</b>	12.2	21.9	5.9	14.3	11.5	23.9
Pharmaceuticals	7.0	11.7	2.8	6.5	5.4	11.7
Bio-Chemicals	3.7	7.5	2.7	7.4	6.0	12.2
Chemicals	1.3	2.5	0.3	0.3	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0

## 7. Trends in Depreciation Expenses

Billions of yen, rounded down

	FY 2010 results		FY 2011 results		FY 2012 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
<b>Depreciation expenses (Consolidated)</b>	10.5	22.1	10.4	22.8	9.4	20.7
Pharmaceuticals	4.5	10.7	6.8	15.3	6.5	13.9
Bio-Chemicals	3.8	6.7	2.6	6.4	2.9	6.7
Chemicals	2.1	4.6	0.9	0.9	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0

## 8. Trends in Employee Numbers

	FY 2010		FY 2011	
	June 30	December 31	June 30	December 31
<b>Number of staff at end of term (Consolidated)</b>	7,554	7,484	7,305	7,229
Pharmaceuticals		5,041		5,390
Bio-Chemicals		1,581		1,632
Chemicals		652		--
Other		210		207

## 9. Exchange rates

	FY 2010 results		FY2011 results		FY 2012 forecasts	
	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31	January 1 to June 30	January 1 to December 31
US Dollar (¥/US\$)	91	88	82	80	77	77
Euro (¥/Euro)	121	116	115	111	98	98
Pound (¥/Pound)	139	136	133	128	119	119

## II. Consolidated Subsidiaries and Affiliates

(As of December 31, 2011)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of anti-body technology (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
			Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
			Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
		Europe	ProStrakan Group plc	100.0%	Supervision and management of special companies (UK)
			Strakan International S.a r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
			Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
		Kyowa Hakko Kirin Italia S.r.l.	100.0%	Sales of pharmaceuticals (Italy)	
	Asia	Kirin Kunpeng (China) Bio- Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)	
		Jeil-Kirin Pharm. Inc.	90.0%	Sales of pharmaceuticals (Korea)	
		Kyowa Hakko Kirin (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)	
Kyowa Hakko Kirin (Hong Kong) Co., Ltd.		100.0%	Sales of pharmaceuticals (Hong Kong)		
Kyowa Hakko Kirin (Singapore) Pte. Ltd.		100.0%	Sales of pharmaceuticals (Singapore)		
Affiliate accounted for by the equity method	Europe	ProStrakan AB	50.0%	Sales of pharmaceuticals (Sweden)	
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
			Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BioKyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
			Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US special companies (US)
		Europe	Kyowa Hakko Europe GmbH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Asia	Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
Kyowa Hakko (H.K.) Co., Ltd.	100.0%		Sale and import/export of fine chemicals including amino acids (Hong Kong)		
Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%		Sale and import/export of fine chemicals including amino acids (Singapore)		
Other	Consolidated subsidiary	Japan	Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.
	Affiliate accounted for by the equity method		Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Notes: Changes to the scope of consolidation (January 1, 2011 to December 31, 2011)

Newly consolidated: 11 companies: ProStrakan Group plc and 10 subsidiaries (\*1)

Removed: 4 companies: Kashiwagi Corporation (\*2), Kyowa Hakko Chemical Co., Ltd., Miyako Kagaku Co., Ltd. (\*3), Shinwa Pharmaceutical Co., Ltd. (\*4)

\*1 On April 21, 2011, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan Group plc and as a result ProStrakan Group, and its 10 subsidiaries were newly included in the scope of consolidation.

\*2 As of January 1, 2011, Kashiwagi Corporation was merged with Miyako Kagaku Co., Ltd. and eliminated.

\*3 Kyowa Hakko Chemical Co., Ltd. and its subsidiary Miyako Kagaku Co., Ltd. were removed from the scope of consolidation at the end of the first quarter of the current period following the transfer of all shares of Kyowa Hakko Chemical Co., Ltd. to KJ Holdings Inc. on March 31, 2011.

\*4 Shinwa Pharmaceutical Co., Ltd. was removed from the scope of consolidation as of the second quarter of the current period and all shares in the company were transferred on April 1, 2011.

### III. Non-Consolidated Net Sales by Division (Items and main products)

#### 1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	FY 2010 results		FY2011 results				FY 2012 forecasts	
	January 1 to June 30	January 1 to December 31 (A)	January 1 to June 30	January 1 to December 31 (forecast as at 7/20)	January 1 to December 31 (B)	Change (B/A)	January 1 to June 30	January 1 to December 31
<b>Pharmaceuticals division total</b>	<b>94.1</b>	<b>192.9</b>	<b>104.6</b>	<b>201.2</b>	<b>206.0</b>	<b>107%</b>	<b>103.7</b>	<b>206.3</b>
<b>Indication / Product name</b>								
<i>ESA formulation</i>								
<b>Nesp</b>	<b>17.7</b>	<b>41.7</b>	<b>25.4</b>	<b>50.8</b>	<b>56.4</b>	<b>135%</b>	<b>25.5</b>	<b>50.5</b>
<i>ESA formulation</i>								
<b>Espo</b>	<b>5.7</b>	<b>10.8</b>	<b>2.7</b>	<b>5.3</b>	<b>5.3</b>	<b>49%</b>	<b>2.0</b>	<b>4.0</b>
<b>Nesp/Espo</b>	<b>23.4</b>	<b>52.6</b>	<b>28.2</b>	<b>56.1</b>	<b>61.8</b>	<b>117%</b>	<b>27.5</b>	<b>54.5</b>
<i>Secondary hyperparathyroidism</i>								
<b>Regpara</b>	<b>4.3</b>	<b>9.5</b>	<b>5.3</b>	<b>11.1</b>	<b>11.5</b>	<b>121%</b>	<b>6.3</b>	<b>13.1</b>
<i>Antiallergenic</i>								
<b>Allelock</b>	<b>13.9</b>	<b>26.8</b>	<b>18.1</b>	<b>29.0</b>	<b>29.1</b>	<b>109%</b>	<b>16.9</b>	<b>29.7</b>
<i>Antiallergenic</i>								
<b>Cellect</b>	<b>1.4</b>	<b>2.7</b>	<b>1.3</b>	<b>2.3</b>	<b>2.5</b>	<b>92%</b>	<b>0.9</b>	<b>1.7</b>
<i>Antiallergic eyedrops</i>								
<b>Patanol</b>	<b>4.7</b>	<b>7.5</b>	<b>8.6</b>	<b>11.6</b>	<b>11.4</b>	<b>152%</b>	<b>8.1</b>	<b>11.3</b>
<i>G-CSF</i>								
<b>Gran/Neu-up*1</b>	<b>7.3</b>	<b>14.4</b>	<b>6.7</b>	<b>14.5</b>	<b>14.8</b>	<b>103%</b>	<b>6.3</b>	<b>13.3</b>
<i>Cancer pain</i>								
<b>Fentos*2</b>	<b>0.0</b>	<b>0.8</b>	<b>1.2</b>	<b>2.6</b>	<b>3.1</b>	<b>386%</b>	<b>2.3</b>	<b>4.9</b>
<i>Anticancer</i>								
<b>Farmorubicin*3 / Adriacin</b>	<b>2.4</b>	<b>4.8</b>	<b>0.5</b>		<b>1.0</b>	<b>23%</b>		
<i>Anticancer</i>								
<b>5-FU</b>	<b>1.5</b>	<b>3.1</b>	<b>1.5</b>	<b>2.9</b>	<b>3.1</b>	<b>100%</b>	<b>1.3</b>	<b>2.7</b>
<i>Anticancer</i>								
<b>Navelbine</b>	<b>1.0</b>	<b>2.0</b>	<b>0.8</b>	<b>1.6</b>	<b>1.7</b>	<b>84%</b>	<b>0.7</b>	<b>1.4</b>
<i>Cardiovascular</i>								
<b>Coniel</b>	<b>10.3</b>	<b>21.0</b>	<b>9.6</b>	<b>19.7</b>	<b>19.7</b>	<b>94%</b>	<b>8.7</b>	<b>17.3</b>
<i>Cardiovascular (Hypertension)</i>								
<b>Coversyl</b>	<b>2.0</b>	<b>4.2</b>	<b>1.9</b>	<b>3.9</b>	<b>3.9</b>	<b>94%</b>	<b>1.7</b>	<b>3.4</b>
<i>Cardiovascular</i>								
<b>Inovan / Pre Dopa</b>	<b>1.5</b>	<b>3.0</b>	<b>1.3</b>	<b>2.9</b>	<b>2.8</b>	<b>91%</b>	<b>1.1</b>	<b>2.3</b>
<i>Antiepileptic</i>								
<b>Depakene</b>	<b>5.2</b>	<b>11.0</b>	<b>5.3</b>	<b>11.1</b>	<b>11.2</b>	<b>103%</b>	<b>5.3</b>	<b>10.7</b>
<i>Parkinson's disease</i>								
<b>Permax*4</b>	<b>0.7</b>	<b>2.0</b>	<b>1.1</b>	<b>2.3</b>	<b>2.1</b>	<b>107%</b>	<b>1.0</b>	<b>2.0</b>
<i>Gastrointestinal</i>								
<b>Nauzelin</b>	<b>2.6</b>	<b>5.3</b>	<b>2.3</b>	<b>4.9</b>	<b>4.8</b>	<b>91%</b>	<b>2.4</b>	<b>4.9</b>
<i>Inflammatory bowel disease</i>								
<b>Asacol</b>	<b>0.2</b>	<b>0.7</b>	<b>1.1</b>	<b>2.8</b>	<b>2.8</b>	<b>363%</b>	<b>1.9</b>	<b>4.1</b>
<b>Exports and Technology Out-Licensing</b>	<b>13.1</b>	<b>24.1</b>	<b>11.4</b>	<b>22.4</b>	<b>22.3</b>	<b>92%</b>	<b>16.1</b>	<b>33.3</b>

Notes 1: As of March 1, 2010, manufacturing, sales and other rights for Neu-up were transferred to Yakult Honsha.

Therefore, Gran/Neu-up figures after March 31, 2010 include only sales figures for Gran.

2: Sales of Fentos began June 24, 2010.

3: Sales of Farmorubicin ended December 31, 2010 following completion of our contract with Pfizer.

Therefore, as of January 2011, only amounts for Adriacin have been included in Farmorubicin/Adriacin.

4: Sales of Permax began April 1, 2010.

## 2. ProStrakan

Millions of GBP, rounded down

Pharmaceuticals division	FY 2010 results			FY 2011 results			FY 2012 forecasts	
	January 1 to June 30	July 1 to December 31	January 1 to December 31	January 1 to June 30	July 1 to December 31	January 1 to December 31	January 1 to June 30	January 1 to December 31
Net sales	45	54	100	48	56	105	60	142
Sancuso	4	2	6	4	5	9	7	16
Abstral	7	9	17	12	14	27	18	38
Tostran	1	1	3	2	2	5	2	4
Xomolix	4	3	7	4	4	8	4	9
Rectogesic	4	4	9	4	4	9	5	10
Adcal-D3	10	12	23	11	12	24	11	24
Others	12	20	32	8	12	20	10	38
Gross profit	29	37	67	29	36	65	40	94
Selling, general and administrative expenses	30	31	61	40	34	75	40	80
Operating income (prior to consolidated adjustment)	(0)	6	6	(11)	1	(9)	0	14
Consolidated adjustment					(18)		(16)	(32)
Operating income (after consolidated adjustment)					(16)		(16)	(17)

\*FY 2010 and FY 2011 results based on ProStrakan local accounting standards (IFRS) while FY 2012 forecasts are presented after consolidated adjustments. Amortization of goodwill is the amortization of the goodwill and noncurrent intangible assets (sales rights, etc.) resulting from the acquisition of all outstanding shares in ProStrakan Group plc.

\*Sales ratio by region

	UK	Europe (excluding UK)	USA	Other	Total
(January 1 to December 31, 2011)	35.9%	46.8%	16.1%	1.2%	100.0%

## 3. Kyowa Hakko Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	FY 2010 results			FY 2011 results			FY 2012 forecasts	
	January 1 to June 30	January 1 to December 31 (A)	January 1 to June 30	January 1 to December 31 (forecast as at 7/20)	January 1 to December 31 (B)	Change on January 1 to December 31 (B/A)	January 1 to June 30	January 1 to December 31
Bio-Chemical division total	28.7	54.2	25.9	50.9	49.6	92%	26.2	52.3
Pharmaceuticals / Industrial raw materials								
Amino acids	10.8	20.4	10.1	19.7	19.1	94%	10.0	20.1
Nucleic acids and vitamins	2.5	4.8	2.7	5.2	5.2	107%	2.5	5.1
Other	3.9	8.0	3.8	7.2	7.2	90%	3.3	6.8
Health care products	4.9	9.8	4.7	9.3	9.3	95%	5.2	10.5

## 4. Kyowa Hakko Chemical

Billions of yen, rounded down

Chemicals division (non-consolidated)	FY 2010 results			FY2011 results
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31
Chemicals division total	19.3	39.7	85.7	22.9
Solvents	7.4	15.9	33.4	8.4
Raw materials for plasticizers	6.3	12.2	27.7	7.7
Specialty chemicals	4.6	9.9	21.2	5.9

Note: The Chemicals Business was discontinued at the end of the first quarter following the transfer of all shares of Kyowa Hakko Chemical on March 31, 2011. As a result, income from Chemicals are until the first quarter ended March 31, 2011.

R&D PIPELINES

Filed • Approved

As of Jan 24th 2012

Therapeutic Area	Code Name Generic Name	Mechanism of Action	Stage		Indication	Formulation	In-House or Licensed	Remarks
			Japan	Other Countries				
Oncology	KW-0761 Mogamulizumab	Anti-CCR4 Humanized Antibody	Filed Apr2011		Adult T-cell Leukemia/Lymphoma	Injection	In-House	( 8 ) POTELLIAGENT®
	Pegfilgrastim	Long-Acting Granulocyte Colony Stimulating Factor		Filed in Asia	Chemotherapy induced Febrile Neutropenia	Injection	Kirin-Angen	Asia: Korea and Vietnam
Nephrology	Cinacalcet Hydrochloride	Calcium Receptor Agonist		Filed in Asia	Secondary Hyperparathyroidism	Oral	Licensed from NPS	Asia: Philippine, Malaysia, Thailand and China
	Darbepoetin Alfa	Long-Acting Erythropoiesis Stimulating Agent		Approved in Singapore Jan/2012	Renal Anemia (on Dialysis)	Injection	Kirin-Angen	
CNS	KW-6000 Apomorphine Hydrochloride	Dopamine Receptor Agonist	Filed Jul2011		Parkinson's Disease	Injection	Licensed from Britannia Pharmaceuticals Limited	
	KW-6002 Isradefylline	Adenosine A2a Receptor Antagonist		Filed in USA	Parkinson's Disease	Oral	In-House	Reimbursement of License from Valeant International SRL for the Development and Commercialization of KW-6002 in the US and Canada.
Other	AM5631 Romiplostim	Thrombopoietin Receptor Agonist		Filed in Asia	Idiopathic (immune) Thrombocytopenic Purpura	Injection	Kirin-Angen	Asia: Singapore and Taiwan (Approved in Malaysia on December 2)

Phase II, Phase III

Therapeutic Area	Code Name Generic Name	Mechanism of Action	Stage		Indication	Formulation	In-House or Licensed	Remarks
			Japan	Other Countries				
Oncology	KW-0761 Mogamulizumab	Anti-CCR4 Humanized Antibody		Phase I / II in USA	Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma	Injection	In-House	( 8 ) POTELLIAGENT®
				Phase II	Adult T-cell Leukemia/Lymphoma Add-on Therapy (for Untreated Patients)			
				Phase II	Peripheral T-NK-cell Lymphoma			
	KW-3246 Fentanyl citrate	µ-Opioid Receptor Agonist		Phase II	Cancer Pain	Sublingual Tablet	Licensed from Oxeo	
	KRN125 Pegfilgrastim	Long-Acting Granulocyte Colony Stimulating Factor		Phase II	Chemotherapy induced Febrile Neutropenia	Injection	Kirin-Angen	
	ARG 197 Ivanditinib	c-Met Inhibitor		Phase II in Japan and Korea	Gastric Cancer	Oral	Licensed from ArQule	
	KW-2478	HSP90 Inhibitor		Phase II in Japan, Korea and Taiwan	Lung Cancer			
Nephrology	KRN321 Darbepoetin Alfa	Long-Acting Erythropoiesis Stimulating Agent		Phase II in Japan and Korea	Myelodysplastic Syndrome related Anemia	Injection	Kirin-Angen	Launched in Japan for Anemia of CKD patients
	KRN483 Cinacalcet Hydrochloride	Calcium Receptor Agonist		Phase II	Hypercalcemia with Parathyroid Carcinoma or Intactable Primary Hyperparathyroidism	Oral	Licensed from NPS	Launched in Japan for Secondary Hyperparathyroidism
	KRN321 Darbepoetin Alfa	Long-Acting Erythropoiesis Stimulating Agent		Phase II in China Phase III in India	Pediatric Renal Anemia	Injection	Kirin-Angen	Launched in Japan for Anemia of CKD patients
Immunology/Allergy	ASKP1240	Anti-CD40 Fully Human Antibody	Phase I	Phase II in USA	Organ Transplant Rejection	Injection	In-House	Jointly Developed with Astellas
	KHK4563 Benralizumab	Anti-I.L5 Receptor Humanized Antibody		Phase II in Japan and Korea	Asthma	Injection	In-House	Being Developed by MedImmune as MEDI-563 Worldwide except in Japan and other Asian Countries POTELLIAGENT®
CNS	Z-206 Mesalazine	pH Dependent Controlled Release Tablet	Phase II		Crohn's Disease	Oral	Licensed from Zeria Pharma.	Jointly Developed with Zeria Pharma Launched in Japan for Ulcerative Colitis.
	KW-6002 Isradefylline	Adenosine A2a Receptor Antagonist	Phase II		Parkinson's Disease	Oral	In-House	
	KW-6485 Topiramate	Antiepileptic Drugs	Phase II		Pediatric Epilepsy	Oral	Licensed from Janssen Pharmaceutical K.K.	Launched in Japan for Use as an Epileptic Drug
Other	KW-3387 Aristotrombin	Recombinant Human Antithrombin	Phase II	Phase I in Europe	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Injection	In-House	

Phase I

Therapeutic Area	Code Name Generic Name	Mechanism of Action	Stage		Indication	Formulation	In-House or Licensed	Remarks
			Japan	Other Countries				
Oncology	KW-2450	IGF-1 Receptor Signal Inhibitor		Phase I / II in USA	Cancer	Oral	In-House	
	KRN330	Anti-AX3 Fully Human Antibody		Phase I / II a in USA	Cancer	Injection	In-House	
	BIW-8962	Anti-GM2 Humanized Antibody		Phase I / II a in USA	Cancer	Injection	In-House	POTELLIAGENT®
	KRN951 Tivozanib	VEGF Receptor Inhibitor	Phase I		Cancer	Oral	In-House	
	KHK2866	Anti-NB-EGF Humanized Antibody		Phase I in USA	Cancer	Injection	In-House	POTELLIAGENT®
	LY2523555 Liranesib	M phase Kinase Egfr Inhibitor	Phase I		Cancer	Injection	In-House	Worldwide Outlicensed to Eis Lilly for the Development and Commercialization of LY2523555 except Japan
	CEP-372509H/2804	Anti-Tumor Specific Glycoprotein Humanized Antibody		Phase I in USA	Cancer	Injection	Cephalon	Jointly Developed with Cephalon POTELLIAGENT®
Nephrology	KHK2898	Anti-CD98 Fully Human Antibody		Phase I in Singapore	Cancer	Injection	In-House	POTELLIAGENT®
Immunology/Allergy	RTA402 Baroxolone Methyl	Antioxidant Inflammation Modulator	Phase I		Diabetic Nephropathy	Oral	Licensed from Resta	
Other	KHK4927	Anti-I.L-17 Receptor Fully Human Antibody	Phase I		Psoriasis	Injection	Kirin-Angen	
	KHK6188	Cannabinoid CB2 Receptor Agonist	Phase I		Neuropathic Pain	Oral	In-House	
	KRN23	Anti-FGF23 Fully Human Antibody		Phase I / II in USA and Canada	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)	Injection	In-House	

( 8 ) KW-0761 is outsourced to Angen Inc. on March 09, 2008, with an exclusive right to develop and commercialize KW-0761 worldwide, except in Japan, Korea, China and Taiwan. Kyowa Hakko Kirin has retained the development and commercialization rights in these countries. In 2010, Kirin paid Angen US\$20M for the buy-out of Angen's option to assume the development and commercialization of KW-0761 in oncology setting in Angen's licensed territory, which was granted under the License Agreement.

Updated since Oct 20th, 2011 (Area, Stage, Filed, Approved, Launched, etc)  
 \* New indication

Withdrawal of Application

Therapeutic Area	Code Name Generic Name	Mechanism of Action	Stage		Indication	Formulation	In-House or Licensed	Reason
			Japan	Other Countries				
Oncology	KRN321 Darbepoetin Alfa	Long-Acting Erythropoiesis Stimulating Agent	Filed Nov2008		Chemotherapy induced Anemia	Injection	Kirin-Angen	The withdrawal of application was made because currently submitted data is insufficient to establish an evidence that is necessary to attain the approval, as a result of discussion with Pharmaceuticals and Medical Devices Agency.